Oxandrolone Withdrawal: What Providers and Prescribers Need to Know in 2026

On June 28, 2023, the FDA finalized the withdrawal of approval for all commercially manufactured oxandrolone products in the United States. For prescribers who relied on Oxandrin or generic equivalents for patients with muscle wasting, catabolic states, burn recovery, Turner syndrome, or HIV/AIDS-related weight loss, this regulatory change created an immediate access challenge that persists into 2026. This guide provides a clear-eyed overview for clinical providers.

Regulatory Background: Why Was Approval Withdrawn?

The FDA's action was grounded in two primary concerns:

1. Boxed warning safety profile: Oxandrolone's labeling carried serious warnings for peliosis hepatis (blood-filled hepatic cysts potentially causing liver failure and intra-abdominal hemorrhage), hepatocellular carcinoma (sometimes fatal), and atherogenic lipid changes. The FDA specifically cited these as "sufficiently serious" to warrant removal from the commercial market.

2. Historic efficacy questions: As far back as January 1984, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee unanimously concluded there was insufficient evidence of efficacy for oxandrolone for most of its approved indications. This finding informed the agency's 2022–2023 withdrawal process.

Notably, the withdrawal was initiated by the manufacturers themselves — Gemini Laboratories (NDA holder for Oxandrin) and Sandoz (generic ANDA holder) both requested the FDA withdraw approval. The FDA also withdrew the ANDAs held by Upsher-Smith and Par Pharmaceutical. The process was a collaborative market exit, not a forced recall against the manufacturers' will.

Current Legal and Regulatory Status in 2026

Oxandrolone remains a DEA Schedule III controlled substance (non-narcotic) under the Anabolic Steroids Control Act of 1990. Prescribing the drug remains legal for licensed providers with DEA registration. The withdrawal of FDA approval from commercial products does not make prescribing illegal — it eliminates the commercially manufactured supply chain, not the prescriber's legal authority.

Key regulatory points for prescribers:

• A Schedule III prescription is required — no refills beyond 5 within 6 months, and states may impose additional restrictions
• The prescription must be fulfilled at a licensed 503A compounding pharmacy that is separately DEA-registered for Schedule III substances
• Compounding must be done on a patient-specific basis — 503B outsourcing facilities cannot compound Schedule III controlled substances at scale
• The compounded product is not FDA-approved — informed consent and clear patient communication about this distinction is important

Clinical Indications and Evidence Base

Despite the commercial withdrawal, there is substantial published literature supporting the use of oxandrolone in specific clinical scenarios:

• Severe burn injuries: Multiple meta-analyses support the use of oxandrolone in severe burn patients, showing significant reduction in catabolic weight loss, improved lean body mass, enhanced donor-site wound healing, and decreased ICU and total hospital length of stay.
• HIV/AIDS-related wasting: Strong evidence supports lean mass improvement and quality-of-life benefits in HIV-related muscle wasting. Oxandrolone was widely adopted in burn and HIV units globally before its commercial withdrawal.
• Turner syndrome: Clinical practice guidelines from a multidisciplinary international conference (NIH, 2007) noted that a non-aromatizable anabolic steroid such as oxandrolone could be considered as an adjunct to growth hormone for girls with extreme short stature in Turner syndrome.
• Corticosteroid-induced catabolism: Adjunctive use in patients receiving prolonged corticosteroid therapy to mitigate protein catabolism and lean mass loss has been documented in clinical literature.

Prescribing Pathway for Compounded Oxandrolone

To prescribe compounded oxandrolone in 2026, providers should follow this pathway:

1. Confirm your DEA registration is current for Schedule III substances.
2. Establish a relationship with a PCAB-accredited 503A compounding pharmacy that handles controlled substance compounding.
3. Write a complete, patient-specific prescription specifying strength (e.g., 2.5 mg or 10 mg), dosage form (oral tablet), quantity, and directions.
4. Inform the patient that the compounded product is not FDA-approved and is prepared on a patient-specific basis. Document this discussion.
5. Plan for monitoring: LFTs, lipid panel, CBC as clinically indicated. In pediatric patients, bone age X-rays to monitor premature epiphyseal closure.

Therapeutic Alternatives to Consider

For patients who cannot access or afford compounded oxandrolone, the following alternatives are clinically reasonable depending on indication:

• Testosterone cypionate/enanthate: First-line for hypogonadism-related muscle wasting; broadly covered; generic available <$30/month
• Nandrolone decanoate: High anabolic-to-androgenic ratio; injectable; well-studied for muscle wasting and anemia of chronic kidney disease; available via compounding
• Stanozolol: Oral; comparable anabolic profile; available via compounding; more hepatotoxic and dyslipidemic than oxandrolone
• Bisphosphonates (for osteoporosis pain): Preferred first-line agents for osteoporosis-related bone pain per current guidelines

How medfinder Can Support Your Patients

When you prescribe compounded oxandrolone, patients often face significant difficulty locating a pharmacy willing and able to fill the prescription. medfinder for providers contacts pharmacies on behalf of your patients to identify which ones can fill specific prescriptions — reducing the burden on patients and your staff to make repeated calls.

Key Takeaways for Clinical Practice

• Commercial oxandrolone (Oxandrin and generics) was permanently withdrawn from the US market on June 28, 2023
• Prescribing remains legal; fulfillment is via DEA-registered 503A compounding pharmacies only
• Compounded oxandrolone is not FDA-approved — inform patients and document the discussion
• For most indications, testosterone therapy is the most accessible alternative; nandrolone decanoate is the closest anabolic-to-androgenic ratio match
• Monitor LFTs, lipid panel, and clinical response in patients receiving any anabolic steroid therapy